Skip to main content

Table 1 Demographic and biochemical laboratory data among the studied groups

From: Study on molecular expression of long non-coding RNA Glypican3 in hepatocellular cancer patients

Variable

HCC

group I,

n = 70

Cirrhosis

group II,

n = 44

Control

group III,

n = 30

P1

value

P2

value

P3

value

Sex

Females: n (%)

Males: n (%)

10 (14.3%)

60 (85.7%)a,b

25 (56.8%)

19 (43.2%)

11 (36%)

19 (64%)

0.1

 < 0.001

0.037

Age (years)

57.5 ± 6.7a,b

42 ± 9.8

39.6 ± 10

0.5

 < 0.001

 < 0.001

T-bilirubin (mg/dl)

1.36 ± 0.89a,b

0.8 ± 0.34

0.83 ± 0.21

0.9

 < 0.001

0.009

AST (U/L)

68.7 ± 35.5a

57.6 ± 37a

30.2 ± 6.1

0.008

0.2

 < 0.001

ALT (U/L)

55 ± 29.9a

61 ± 32.7a

24.5 ± 7.4

 < 0.001

0.5

 < 0.001

Albumin (g/dl)

3.3 ± 0.6a,b

4.3 ± 0.76

4.27 ± 0.6

0.9

 < 0.001

 < 0.001

PC (%)

74 ± 11a,b

86 ± 10

87 ± 8.6

0.9

 < 0.001

 < 0.001

Platelets × 103/m3

132.8 ± 63.9a,b

228 ± 69a

279.6 ± 88

0.019

 < 0.001

 < 0.001

AFP (ng/ml)

109 ± 40a,b

10 ± 4

5.13 ± 2.9

0.009

0.001

0.9

GPC3 (ng/ml)

6.3 ± 2.26a,b

3.9 ± 0.8

3.76 ± 2.06

 < 0.001

 < 0.001

0.9

lncRNA AF085935

1.6 ± 0.8a,b

0.95 ± 0.5

0.68 ± 0.2

 < 0.001

 < 0.001

0.29

Child–Pugh score of the HCC group

 A

Number of patients

%

 

25

35.7%

 B

12

17%

 C

33

47.3%

Imaging data of the HCC group

No. of FL

 

Number of patients

%

 

1

41

58.5%

2

12

17%

Multiple

17

24.5%

Site of FL

Right lobe

55

78.5%

Left lobe

5

7.0%

Both lobes

10

15.5%

Vascular invasion

Yes

50

71.4%

No

20

28.6%

Abdominal LNs

yes

45

64.0%

no

25

36.0%

  1. Data were expressed as mean ± SD, p value < 0.05 was significant. P1 value: HCC group versus the control group; P2 value: HCC group versus the cirrhosis group; P3 value: cirrhosis group versus the control group
  2. T-bilirubin Total bilirubin, D-bilirubin Direct bilirubin, AST Aspartate transaminase, ALT Alanine transaminases, PC Prothrombin concentration, No FL Number of focal lesion, LN Lymph node
  3. aSignificant difference versus control subjects
  4. bSignificant difference versus cirrhosis subjects